Abstract. The effects of tamoxifen (TAM) treatment on bone metabolism and skeletal growth were studied in sexually mature intact or ovariectomized (OVX) rats. Experiment 1 was designed to observe the effects of TAM on bone metabolism and skeletal growth in intact rats and included two groups: (1) intact plus vehicle and (2) intact plus TAM. Experiment 2 was designed to investigate the effects of TAM on OVX rats and included the other two groups: (3) OVX plus vehicle and (4) OVX plus TAM. Serum calcium osteocalcin and urinary pyridinoline (Pyr) and deoxypyridinoline (Dpyr) were measured serially before and after TAM treatment for 6 weeks in order to monitor bone turnover. Bone mineral density (BMD) and bone mineral content (BMC) of excised right femora and lumbar vertebrae were determined by dual energy X-ray absorptiometry (DXA). To examine the effect of TAM on skeletal growth, the conventional parameters of femora and the histology of right tibiae were also measured. TAM did not induce significant change in the biochemical markers in intact rats during the 6-week experiment. Bone mass and skeletal growth were not changed by TAM treatment in intact rats. However, TAM treatment reduced the increase in serum osteocalcin and urinary pyridinium cross-links from 1 week to 6 weeks postovariectomy in the OVX rats. TAM inhibited the skeletal growth in OVX rats, because TAM treatment shortened femoral length and decreased the cell number in the growth plate in OVX rats in this study. Our findings indicate that TAM exerts an effect of estrogen agonist on bone metabolism and skeletal growth in OVX rats, however, it does not affect them in intact rats.
The advance in the determination of biochemical markers of bone turnover and bone mass could make the experimental design more efficient and practical. The measurement of urinary pyridinium cross-links, i.e., pyridinoline (Pyr) and deoxypyridinoline (Dpyr), are regarded as sensitive markers of bone resorption [1] , and they showed better discriminatory ability than hydroxyproline in patients with metabolic bone disorders [2] . Egger et al. [3] also suggested that urinary excretion of pyridinium cross-links closely reflected bone resorption in rats. Serum osteocalcin has been commonly employed as a bone formation marker clinically and used to assess the effects of experimental agents on bone metabolism in several animal models [4] [5] [6] [7] . Dual energy X-ray absorptiometry (DXA) has proved to be a precise and reliable method for bone mineral density (BMD) and bone mineral content (BMC) measurements in rats in vitro [8] and in vivo [9] . Though the effects of TAM on bone metabolism and bone mass in the OVX rat had been evaluated by conventional methods [10, 11] and the histomorphometric technique [12, 13] , reports evaluating its effects on intact animals has been less often published. Since TAM is also widely used in the management of premenopausal breast cancer, the effect of TAM on bone with normal estrogen levels should also be concerned. Furthermore, at present, there have been no data on the effects of tamoxifen on urinary excretion of pyridinium cross-links. The aim of this study was to evaluate the effect of TAM on bone metabolism and skeletal growth in intact or ovariectomized (OVX) rats using biochemical markers, DXA, and histological methods.
Materials and Methods

Protocol Experiment 1.
To investigate the effects of TAM on bone in intact rats, 16 sexually mature (3 months old) female Wistar rats were randomly divided into two groups (n ‫ס‬ 8 each). One group received the solvent vehicle (Intact + Vehicle) and the other was injected with TAM (Intact + TAM) which was dissolved in 70:30 ethanol-water subcutaneously once a week for 6 weeks at a dosage of 20 mg/kg body weight.
Experiment 2.
To investigate the effects of TAM on bone in rats with estrogen deficiency, two groups were OVX. Under general anesthesia, bilateral ovariectomies were performed from a dorsal approach in 16 animals. One group (n ‫ס‬ 8) received the solvent vehicle (OVX + Vehicle) and the other (n ‫ס‬ 8) was injected with TAM (OVX + TAM) by the same protocol as in experiment 1.
Treatments lasted 6 weeks. The animals were maintained on normal rat chow and housed with a 12-hour light-dark cycle. Tap water was supplied ad libitum. Blood (1000 hour-1200 hour) and 24-hour urine samples were collected on the first day and at 1, 2, 4, and 6 weeks after treatment. The animals were sacrificed at 6 weeks after the commencement of the experiment and the right femora and lumbar vertebrae were excised for determination of BMC and BMD. The right tibiae were excised for histological examination.
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Biochemical Markers
Serum calcium was measured according to standard laboratory procedures. Serum osteocalcin was measured by sandwich enzyme immunoassay using a monoclonal antibody against rat intact osteocalcin. Urinary Pyr and Dpyr were measured as previously described [14] . The values of Pyr and Dpyr in urine samples were expressed per mmol of urinary creatinine. Before hydrolysis, urinary creatinine content was determined enzymatically with an aliquot of each urine sample using a clinical chemistry analyzer (CL-20, Shimadzu, Japan). Using our protocol, the recoveries of standard Pry and Dpyr were 75.4 ± 2.3% for Pyr and 73.1 ± 2.9% for Dpyr. The coefficients of variation of Pyr and Dpyr for several measurements, performed at different weeks, on the same urine sample were 8.3% and 9.5%, respectively.
Bone Mineral Measurements
BMC and BMD of excised femora and lumbar vertebrae were measured by DXA using a Hologic QDR-1000 plus bone densitometer (Hologic, Inc., Waltham, MA) adapted for measurement in small animals. A regional high-resolution software program (line spacing 0.0254 cm and resolution 0.0127 cm) was used with a 1-mm diameter X-ray collimator that was simply inserted over the original collimator. Excised femora and lumbar vertebrae were put into a container full of water on the acrylic scanning platform. The lumbar spine was scanned at the levels of vertebrae L1-6 and the femora was scanned for whole size. The coefficients of variation of BMC and BMD for several measurements performed at different days on the same sample were 0.375% and 0.374% for femora and 1.756% and 0.987% for lumbar spine, respectively.
Measurement of Bone and Histology
After densitometry, the length of femora was measured with a pair of digital calipers; the volumes of femora were measured according to Archimedes' principle. After the right femora were dried at 120°C for 12 hours and ashed in a muffled furnace at 800°C for 12 hours, dry and ash weight were measured. Bone density was calculated by dividing dry weight by volume. The right tibiae were processed according to a standard pathological procedure for hematoxylin and eosin (H&E) stain and observed under a microscope. The width of the growth plate and the cell number in the proliferative zone and the hypertrophic cartilage zone were measured under a microscope; 10 columns from the proliferative zone and the hypertrophic cartilage zone in epiphyseal cartilage were measured, and the cell number was calculated as the mean of 10 columns and expressed as the number per column.
Statistical Analysis
The significance of difference between the two groups was evaluated with unpaired two-tailed Student's t-test, using StatView II on a Macintosh computer. Simple linear regression was used to analyze the correlation between the ash weight of femur and the BMC of femur. Data are expressed as means ± SE (standard error of the mean) except special notification. Values of P less than 0.05 were considered significant.
Results
Body Weight
Intact and OVX rats treated with TAM had significantly lower body weight than the respective controls (Fig. 1) . TAM treatment significantly decreased the gain in body weight in both intact and OVX rats.
Biochemical Markers
TAM had no effect on the serum calcium in either intact or OVX rats (data not shown). TAM did not induce significant changes in serum osteocalcin and urinary excretion of pyridinium cross-links in the intact rats (Fig. 2) . Ovariectomy resulted in a significant increase in serum osteocalcin and urinary excretion of pyridinium cross-links at 1 week postoperation and remained at a high level throughout the experiment. TAM significantly inhibited the increase in serum osteocalcin and urinary pyridinium cross-links due to ovariectomy from 1 week to 6 weeks postoperation (Fig. 3) .
DXA of Rats
Accuracy. Regression analysis demonstrates that ash weight of femora and femoral BMC by DXA were closely and linearly correlated in animals ranging in weight from 220 to 330 g (Fig. 4) . TAM treatment did not significantly change the BMD of femur and lumbar vertebrae in the intact rats (Table 1) . TAM slightly increased the BMD in femur and lumbar vertebrae from the OVX rats, but not significantly ( Table 2) .
Assessment of Bone Weight, Volume, and Density
TAM treatment did not change the length, volume, ash weight, and density of femur in intact rats ( Table 1) . The OVX + TAM group had significantly shorter femora and less volume of femora than OVX + Vehicle after the 6-week administration. OVX + TAM group also had more bone density than OVX + Vehicle, but not a significant amount (Table 2) . 
Histological Findings
To investigate the reason that TAM shortened the length of femora, the growth plate of tibiae was examined histologically. TAM significantly decreased not only the width of the growth plate but also the cell number in the proliferative zone and the hypertrophic cartilage zone in OVX rats ( Fig.  5 and Table 2 ), TAM did not induce these changes in intact rats ( Fig. 5 and Table 1 ).
Discussion
In this study we confirmed that TAM specifically blocked the estrogen-dependent high turnover of bone induced by ovariectomy, as indicated by the changes in serum osteocalcin and urinary pyridinium cross-links. TAM exerted an effect of estrogen agonist on bone metabolism in sexually mature OVX rats, but it also inhibited skeletal growth in them. However, it did not change bone remodeling and skeletal growth in intact rats.
Our results showed that TAM decreased the body weight in the rats with and without estrogen deficiency (Fig. 1) . Moon et al. [15] also observed the dose-dependent inhibitory effect of tamoxifen on weight gain in both intact and OVX rats. It is known that estrogen exhibits inhibitory effects on growth in OVX rats. As was found in earlier studies, this result can be explained by TAM exerting the effect of an agonist of estrogen on growth.
Serum osteocalcin levels have been generally reported to increase in postmenopausal and OVX women [4] , with estrogen treatment restoring those levels to the normal range [16] . The pyridinium cross-links are thought not to be metabolized and their urinary excretion is not affected by dietary content. As was found in earlier studies [17, 18], we have confirmed that measurement of urinary cross-links excretion provides a more specific indicator of bone resorption than hydroxyproline in humans [2] . In the rat, Black et al. [19] showed that an increase in the amount of urinary crosslinks excretion reflected bone resorption in OVX rats. Egger et al. [3] proved urinary cross-links excretion was not influenced by the diet and suggested that excretion of pyridinium cross-links closely reflected bone resorption in the rat. In this study, TAM suppressed the increase in serum osteocalcin and urinary pyridinium cross-links from 1 week to 6 weeks postoperation in the OVX rats. Estrogen is usually thought to maintain bone mass by inhibiting bone resorption and formation. TAM mimicked estrogen effects on bone remodeling in OVX rats in this study. On the other hand, TAM did not cause significant changes in serum os- Fig. 2 . Effects of TAM on serum osteocalcin and urinary excretion of pyridinium cross-links in intact rats. Pyr, pyridinoline; Dpyr, deoxypyridinoline. Data are given as mean ± SE, n ‫ס‬ 8 for each group. Fig. 3 . Effects of TAM on serum osteocalcin and urinary excretion of pyridinium cross-links in OVX rats. *P < 0.05, **P < 0.01, ***P < 0.001 vs. OVX + TAM. Pyr, pyridinoline; Dpyr, deoxypyridinoline. Data are given as mean ± SE, n ‫ס‬ 8 for each group.
teocalcin and urinary excretion of pyridinium cross-links in intact rats. To our knowledge, this is the first report on the effect of TAM on urinary excretion of pyridinium crosslinks in rats. The effects of TAM on serum osteocalcin and urinary pyridinium cross-links in OVX rats showed that it acted as an estrogen agonist on bone turnover.
In agreement with the study by Goulding and Gold [20], we found that TAM decreased the growth of femur only in OVX rats. Rats grow throughout their lives and the epiphyses do not close. Therefore, the length of the femur is possibly a good indication of the growth rate in lifetime studies of rats. Bone growth is regulated by humoral as well as local factors; insulin-like growth factor I (IGF-I) is one of the most abundant factors known to increase the longitudinal growth rate in animals [21] and TAM was reported to lower circulating IGF-I in OVX rats [22] . The lower levels of IGF-I induced by TAM may explain the inhibition of skeletal growth in TAM-treated OVX rats. Estrogen had been proven to inhibit skeletal growth in rats [23] . In this study, TAM showed the same effect on skeletal growth as estrogen in OVX rats. Intact rats with normal plasma estrogen levels may retain sufficient IGF-I to maintain normal growth of the femur against the effect of TAM on IGF-I levels.
It was hypothesized that the action of TAM on bone is influenced by the ambient level of circulating estradiol [24] , that is, TAM has an estrogen agonist effect on bone at low levels of estradiol as in OVX animals; it has an antiestrogen effect on bone in the presence of high plasma estrogen levels. We observed the inhibitory effects of TAM on the high turnover of bone in the OVX animals, however, the anti-estrogen effect of TAM on bone turnover was not observed in intact rats. TAM had no effect on the bone turnover of intact rats, indicating that TAM specifically blocks estrogen-dependent high turnover of bone. In this study, TAM exhibited different effects on bone turnover and skeletal growth in rats with and without estrogen deficiency. Perhaps TAM can easily bind with an estrogen receptor and exerts the effect as estrogen in rats with estrogen deficiency; however, in intact animals without estrogen deficiency, TAM binds less efficiently to the estrogen receptor because of the interference from estrogen.
Despite conflicting reports on the effects of TAM on bone mass in animals [10] [11] [12] , the histomorphometric studies in humans and rats suggest that TAM mimics the effects of estrogen on bone metabolism [25, 26] . Our results on biochemical markers are consistent with those histomorphometric findings. The effect of TAM on skeletal growth in this study was observed by the length of femur and the histology; further study of histomorphometry at the secondary spongiosa may be needed.
In conclusion, TAM exhibited the action of estrogen agonist on bone turnover and skeletal growth in sexually mature OVX rats; however, it did not affect bone in intact rats. 
